IMA
ImageneBio Inc
There isn't enough reported data to score IMA yet.
IMA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
IMA's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
IMA PE Valuation
IMA has no meaningful PE right now: it lost money over the past year.
IMA Forward outlook
There aren't enough analyst estimates for IMA to show an outlook.
IMA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$8.19 | +$6.45 |
| Q2 2025 | -$7.80 | +$9.12 |
| Q1 2025 | -$10.44 | +$8.40 |
| Q4 2024 | -$12.24 | +$7.32 |
| Q3 2024 | -$14.64 | +$4.68 |
| Q2 2024 | -$16.92 | +$3.36 |
| Q1 2024 | -$18.84 | +$3.00 |
| Q4 2023 | -$19.56 | +$3.24 |
IMA is still losing money, but far less than before: $8.19 per share over the past year, against $22.80 at its worst in late 2022.
IMA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2023 | $659K | -88% |
| Q3 2023 | $1.2M | -81% |
| Q2 2023 | $2M | +425% |
| Q1 2023 | $5.3M | +57% |
| Q4 2022 | $5.5M | -73% |
| Q3 2022 | $6.4M | +71% |
| Q2 2022 | $382K | -89% |
| Q1 2022 | $3.4M | -2.6% |
IMA's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2023 | -3324% | -3047 points |
| Q3 2023 | -1646% | -1367 points |
| Q2 2023 | -923% | +4562 points |
| Q1 2023 | -292% | +209 points |
| Q4 2022 | -277% | -291 points |
| Q3 2022 | -279% | +108 points |
| Q2 2022 | -5485% | -5127 points |
| Q1 2022 | -501% | -221 points |
IMA's operating margin was −3324% last quarter, down 3047 points from the same quarter a year ago, near the bottom of its range since 2021.
IMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.5M | +$17.1M |
| Q2 2026 | -$9.1M | -$5.7M |
| Q1 2026 | -$14.8M | -$4.2M |
| Q4 2023 | -$22.1M | -$4.2M |
| Q3 2023 | -$20M | -$1.6M |
| Q2 2023 | -$18.1M | +$1.3M |
| Q1 2023 | -$19.9M | -$119K |
| Q4 2022 | -$17.9M | -$4M |
IMA has burned cash in almost every quarter: −$41M over the past year, against −$63M the year before.
IMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.9% | +961K shares |
| 1 year | +326% | +13.1M shares |
| 3 years | +423% | +13.8M shares |
IMA has 17M diluted shares, up 326% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
IMA Net Leverage
IMA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
IMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.2 | Oversold |
| Stochastic | 6.5 | Oversold |
IMA's weekly RSI is 26 (oversold) and its Stochastic is 6 (oversold).
IMA PE vs Healthcare Sector
| Metric | IMA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
IMA has no meaningful PE right now: it lost money over the past year.
IMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.18 | 17% below |
| 20 week MA | $4.95 | 30% below |
| 50 week MA | $5.63 | 39% below |
| 100 week MA | $9.77 | 65% below |
| 200 week MA | $23.0 | 85% below |
IMA is in a downtrend: it's below all five of its weekly moving averages, and 85% below its 200-week average.
IMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $384.0 | $178.1 | -54% |
| 2022 | $178.1 | $34.2 | -81% |
| 2023 | $34.2 | $23.6 | -31% |
| 2024 | $23.6 | $18.5 | -22% |
| 2025 | $18.5 | $5.80 | -69% |
| 2026 YTD | $5.80 | $3.45 | -41% |
IMA has finished every year since 2021 lower, and it's down 41% so far in 2026.